Advanced search×

Risperidone and lamotrigine: no evidence of a drug interaction.

Ingrid Castberg and Olav Spigset

J Clin Psychiatry 67(7):1159 (2006) PMID 16889467

Version: za2963e q8za7 q8zb3 q8zc6 q8zdf q8ze2 q8zfd q8zga

Similar articles you may find interesting…

  1. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
    Roberto Cavallaro, Federica Cocchi, ... Enrico Smeraldi

    J Clin Psychiatry 65(2):187-90 (2004) PMID 15003071

    Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients....
  2. [Risperidone use in child and adolescent psychiatric patients].
    Claire C Chevreuil, Jean-Michel JM Reymann, ... Danièle D Bentué-Ferrer

    Therapie 63(5):359-75 (2008) PMID 19154706

    We have done a review of the literature on the effectiveness and the cautions for prescription of risperidone, a second generation antipsychotic drug. Risperidone has proved helpful in treating children and adolescents with autism spectrum, conduct and bipolar disorders, Tourette's syndrome, and sch...
  3. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
    David M Taylor, Catrin Fischetti, ... Victoria Cornelius

    J Clin Psychiatry 70(2):196-200 (2009) PMID 19026261

    The study included 211 evaluable patients. Over 3 years, 84% of subjects discontinued RLAI; 27.7% of these switched to oral risperidone. The Cox model showed that younger age (p = .001), longer duration of illness (p = .001), inpatient status at initiation (p = .002), and an RLAI dose of 25 mg/2 wee...